Department of Animal Science, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853.
Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853.
J Dairy Sci. 2018 Apr;101(4):3285-3302. doi: 10.3168/jds.2017-13164. Epub 2018 Feb 14.
Our objectives were to determine (1) the effect of a single dose of an oral Ca bolus within 24 h after parturition on plasma Ca concentration, (2) the response of primiparous (PP) and multiparous (MP) cows to this supplementation strategy, and (3) differential responses based on plasma Ca at enrollment. For objective 1, cows from 1 commercial dairy in New York State were enrolled within 19 h after parturition (mean ± standard deviation = 8.3 ± 5.3 h) and randomized within parity group (first, second, and ≥third) to control [CON (n = 25); no placebo] or a single dose bolus treatment [BOL (n = 25); 3 oral Ca boluses supplying 54 to 64 g of Ca]. Plasma Ca was measured repeatedly between 1 and 24 h following treatment. For objectives 2 and 3, cows on 6 commercial farms in New York State were assigned to treatment as for objective 1 (CON, n = 1,973; BOL, n = 1,976). Herd records for health, reproduction, and Dairy Herd Improvement Association test day milk production were collected. Mixed effect multivariable models were developed using repeated measures ANOVA, Poisson regression, or proportional hazard models. Objective 2 analyses considered treatment with periparturient risk factors, whereas objective 3 analyses also considered Ca status. No difference was observed for plasma Ca between 1 and 24 h after treatment. Primiparous cows assigned to BOL calving at >712 d old had decreased risk of one or more health disorders [≤30 d in milk; risk ratio (RR) = 0.65, 95% confidence interval (CI) = 0.51 to 0.84] and those with body condition score >3.5 responded to BOL with increased milk production (CON = 31.7 ± 1.1, BOL = 35.1 ± 1.1 kg/d), as did those with days carried calf >277 (CON = 31.9 ± 1.0, BOL = 34.7 ± 1.0 kg/d). Reduced risk of one or more health disorders was observed in parity ≥3 (RR = 0.85, 95% CI = 0.81 to 0.89) and MP cows with body condition score >3.5 (retained placenta; RR = 0.70, 95% CI = 0.58 to 0.84) or that were lame (displaced abomasum; RR = 0.49, 95% CI = 0.32 to 0.75). Differential responses for PP cows by Ca status were minimal. For MP cows with low plasma Ca, BOL decreased risk of additional Ca treatment (≤1.8 mmol/L; RR = 0.57, 95% CI = 0.40 to 0.80) as well as risk of one or more health disorders (≤2.15 mmol/L; RR = 0.90, 95% CI = 0.85 to 0.95). Supplementation with a single oral dose of Ca could be targeted to periparturient risk groups for improved health. Calcium status did not differentiate responses of PP cows, but MP cows with low Ca at parturition had improved health status when supplemented.
(1) 确定产后 24 小时内单次口服钙补充剂对血浆钙浓度的影响;(2) 研究初产牛(PP)和经产牛(MP)对这种补充策略的反应;(3) 根据入组时的血浆钙水平,研究不同的反应。 为了实现目标 1,我们从纽约州的 1 家商业奶牛场招募了产后 19 小时内的奶牛(平均±标准差=8.3±5.3 小时),并根据胎次组(第一胎、第二胎和≥第三胎)将其随机分为对照组(CON,n=25;无安慰剂)或单次口服钙补充剂治疗组(BOL,n=25;3 次口服钙补充剂,提供 54-64 g 钙)。在治疗后 1 至 24 小时内,我们反复测量血浆钙。 为了实现目标 2 和 3,我们将纽约州 6 家商业奶牛场的奶牛分配为与目标 1 相同的治疗方案(CON,n=1973;BOL,n=1976)。我们收集了牛群的健康、繁殖和奶牛群体改良协会测试日牛奶产量记录。 使用重复测量方差分析、泊松回归或比例风险模型开发了混合效应多变量模型。 目标 2 分析考虑了围产期风险因素的治疗效果,而目标 3 分析还考虑了钙状态。 治疗后 1 至 24 小时内,血浆钙没有差异。 初产牛如果在 >712 天龄时分娩且接受 BOL 治疗,则发生一种或多种健康障碍的风险降低[泌乳期 ≤30 天;风险比(RR)=0.65,95%置信区间(CI)=0.51 至 0.84],且体况评分 >3.5 的牛对 BOL 的反应是增加牛奶产量(CON=31.7±1.1,BOL=35.1±1.1 kg/d),携带牛犊天数 >277 天的牛也是如此(CON=31.9±1.0,BOL=34.7±1.0 kg/d)。 我们发现,≥3 胎次(RR=0.85,95%CI=0.81 至 0.89)和体况评分 >3.5 的 MP 牛(胎衣不下;RR=0.70,95%CI=0.58 至 0.84)或跛行(皱胃移位;RR=0.49,95%CI=0.32 至 0.75)的牛发生一种或多种健康障碍的风险降低。 钙状态对 PP 牛的反应差异很小。 对于血浆钙水平较低的 MP 牛,BOL 降低了额外的钙治疗(≤1.8 mmol/L;RR=0.57,95%CI=0.40 至 0.80)和一种或多种健康障碍(≤2.15 mmol/L;RR=0.90,95%CI=0.85 至 0.95)的风险。 对围产期风险群体进行单次口服钙补充可能会改善健康状况。 钙状态不能区分 PP 牛的反应,但分娩时血钙水平较低的 MP 牛在补充钙后健康状况得到改善。